Gallant Net Worth Shark Tank Update 2025

As beloved pets get older, many owners feel helpless as their animals face arthritis, joint pain, organ issues, and other age-related problems. It is painful to watch a healthy pet slow down, limp, or suffer because we lack options. Pets deserve better, and owners deserve hope. That is the problem at the heart of the story.

Aaron Hirschhorn founded Gallant to offer something new and hopeful. He used stem cell science from his own healing journey and adapted it for dogs and cats. By banking healthy young stem cells, owners could prepare for their pet’s future health. Rather than treating symptoms later, this is proactive and regenerative.

Aaron appeared on Shark Tank Season 11 Episode 8, seeking $500,000 for 2% equity. He brought puppies to the pitch, shared his vision, and explained a model where vets earn $100 per kit, owners pay $95 per year, and Gallant covers storage and research costs. His ask reflected belief in the service’s medical and business potential.

Gallant Net Worth Shark Tank Update 2025

Aaron was looking for an investment of $500k in exchange for 2% equity in the company. At the time of the episode, he valued his company at $25 million. Aaron successfully secured a deal with Lori and Anne for an investment of $500k for 5% equity in the company. The investment adjusted the company’s net worth to around $10 million. After the show was aired, the company experienced a good boost in exposure. As per my rough estimate, the current net worth of Gallant is around $43.5 million.

Shark(s) name	Offer & Demand	Counteroffer	Accepted?
Anne Wojcicki	Partnered with Lori	N/A	N/A
Lori Greiner & Anne Wojcicki	$500,000 for 8% equity (joint offer)	$500,000 for 4% equity (joint offer)$500,000 for 5% equity (joint offer)	Yes
Kevin O’Leary	$500,000 for 2% equity + 2% stock options	Alternative: $500,000 for 1% equity + 10% royalty per kit	No
Daymond John	Out	N/A	Out
Mark Cuban	Out	N/A	Out

Aaron Hirschhorn Backstory & Their Initial Pitch

Aaron Hirschhorn was a pet lover and entrepreneur. He created DogVacay and sold it in 2017. Later, he experienced relief from back pain through stem cell therapy. Watching his dog struggle with arthritis, he imagined giving pets the same chance. Veterinarians perform spay or neuter surgeries and normally discard reproductive tissue. Aaron saw an opening to turn that tissue into something valuable.

He founded Gallant in 2018, built a lab, applied for patents, and began working with vet partners. His vision was to bank stem cells while pets were young and healthy. This way, in the future, owners could use these cells to treat illnesses, regenerative care instead of symptom management.

On Shark Tank, Aaron brought puppies for emotional impact. He explained how he wanted to bank cells that could one day heal joints, reduce arthritis, and extend healthy life. He asked for $500,000 for 2% equity. He shared costs: vets earn $100 per kit, customers pay $95 a year, but Gallant absorbs the upfront collection and storage costs. He described a $25 million valuation backed by $10 million in investments and four patents.

His pitch balanced science, personal story, and numbers. It showed heart and strategy, opening the door for real discussion.

Queries, Shark Responses & Final Deal

During the pitch, the Sharks asked key questions:

Mark Cuban asked how cuts into revenue are addressed. He also looked at scaling logistics. He did not make an offer and stepped out.

Daymond John said the vet and consumer costs looked high. He wanted Anne’s and Lori’s perspectives, and left when they stayed in.

Kevin O’Leary dug into numbers. He noted Gallant was likely losing money on each kit because of lab costs. He offered two deals: $500,000 for 2% equity plus stock options, or $500,000 for 1% equity with a 10% royalty per kit. He wanted returns from each sale, not future value.

Anne Wojcicki expressed concern about pricing and customer adoption. She suggested increasing annual fees to bring better margins and save more money for research.

Lori Greiner believed in the long-term opportunity despite short-term losses. She and Anne partnered for impact. They offered $500,000 for 8% equity. Aaron tried to negotiate. A $500,000 for 4% offer was too low. He then offered 5%, and Lori and Anne accepted it. That became the final deal.

Product Availability

Gallant offers stem cell banking for dogs and cats. Vendors send kits to vets. The vet collects tissue during routine surgery. KITs are shipped to the Gallant lab in California, where cells are isolated, frozen, and stored in liquid nitrogen.

Customers can choose a lifetime plan for $890, or pay a $205 setup fee and $95 monthly or annually. Gallant also sells veterinary stem cell therapy once clinical trials are complete.

Their website, gallant.com, explains the steps and science clearly. They share clinical trial updates, pricing, and partnerships with veterinarians. They are active on social media, including Instagram and Facebook, highlighting research milestones and success stories.

Gallant also works with vet clinics nationwide. They offer off-the-shelf stem cell therapies that are currently being tested in clinical trials in cats and dogs.

What Happened to Gallant After Shark Tank?

After the show, Gallant continued to grow. Despite founder Aaron’s tragic passing in 2021, the company pressed on. They refined pricing, lifetime plans went from $595 to $890, with a $205 setup fee or $95 monthly/annual plan. By 2023, Gallant reached about $5.9 million in annual revenue. They secured additional funding, a $15 million Series A in January 2024, bringing total funding to $43.5 million over three rounds.

The company acquired Cook-Regentec in 2019 to enhance lab operations. They built lab facilities in La Jolla and hired top researchers and veterinarians. They also launched multiple clinical trials, including studies on canine atopic dermatitis, feline gingivostomatitis, chronic kidney disease, osteoarthritis, and more. They started revenue-generating off-the-shelf therapies pending FDA approval.

Leadership shifted to Linda Black, DVM, PhD, as CEO after Aaron’s death. The board includes scientists, vets, and experienced business leaders. As of June 2025, Gallant is operational and growing. They no longer sell directly to consumers; they are scaling clinical services for pets through veterinary networks.

Conclusion

Gallant began from Aaron Hirschhorn’s personal healing journey and pet love. He believed stem cell therapy could help pets, too. On Shark Tank, he pitched a bold vision: bank stem cells drawn during routine surgeries for future regenerative care. Despite early financial losses per kit, he secured a $500,000 deal for 5% of the company with Lori and Anne.

After the show, Gallant survived founder loss but grew stronger. They built clinical labs, raised $43 million, refined pricing, and launched multiple trials. With annual revenue near $6 million and a new CEO in place, Gallant continues its mission.

Aaron’s dream lives on. He aimed to give pets healthier, longer lives, and that legacy stands. Gallant now merges science, compassion, and business to bring healing innovation to homes. Their journey shows how caring for pets can lead to real-world breakthroughs in veterinary medicine.